Xenon Pharmaceuticals' CMO Sells 16.63% of Shares for $78,000, Reduces Direct Ownership to 7,069 Shares.

Xenon Pharmaceuticals' stock rose 55% as its chief medical officer, Christopher John Kenney, sold 1,410 common shares for $78,000. The sale represented 16.63% of his direct common stock holdings, reducing his direct position from 8,479 to 7,069 shares. The sale was tied to vested RSUs that resulted in the delivery of 3,750 common shares, of which 1,410 shares were immediately sold in the open market.